Releases
Akeso Initiates Phase Ib/II Trial for HER3 ADC in Lung Cancer Patients
Akeso has dosed the first patient in a Phase Ib/II clinical study evaluating AK138D1, its next-generation HER3 antibody-drug conjugate. The trial investigates the drug as both a monotherapy and in combination with ivonescimab, targeting advanced non-small cell lung cancer across multiple treatment resistance scenarios.






















